相关实验视频

Updated: Jun 14, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

用药理学甲酸盐准质母细胞多形细胞:通过细胞外H₂O₂来破坏DNA损伤反应和mTOR级联

Naphat Chantaravisoot¹, Kittipong Sanookpan², Onsurang Wattanathamsan²

¹Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Systems Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.

Free radical biology & medicine

|June 9, 2025

概括

药理性酸盐 (P-AscH^-) 通过破坏DNA损伤反应 (DDR) 和mTOR通路,对质母细胞瘤 (GBM) 治疗具有前景. 这种维生素C衍生物诱导细胞毒性并增强现有疗法,为攻击性脑瘤提供了新的希望.

科学领域:

神经瘤学神经瘤学
癌症治疗方法癌症治疗方法
分子生物学分子生物学

背景情况:

多形质母细胞瘤 (GBM) 是一种具有侵略性的脑瘤,治疗选择有限,预后不佳.
转录组分析揭示了GBM细胞中DNA损伤反应 (DDR) 途径的上调,表明潜在的治疗脆弱性.

研究的目的:

调查药理性酸盐 (P-AscH^-),一种高度的维生素C配方,作为GBM的新治疗策略.
阐明P-AscH^-在GBM中发挥抗癌作用的分子机制.

主要方法:

评估了P-AscH^-在低级和高级结质瘤细胞中的细胞毒性.
研究了活性氧物种 (ROS),特别是细胞外H₂O₂在P-AscH^-诱导的细胞死亡中的作用.
分析了P-AscH^-对DNA损伤反应 (DDR) 和mTOR信号通路的影响.
通过使用3D-GBM球形模型,评估P-AscH^-与temozolomide和mTOR抑制剂结合的协同效应.

主要成果:

P-AscH^-通过细胞外H₂O₂生产诱导ROS介导的细胞毒性在质瘤细胞中.
生成的H₂O₂通过准关键调节器 (Chk1, RPA2) 损害DDR信号,并过度激活PARP1.
P-AscH^- 破坏了mTORC1和mTORC2信号通路,主要基质 (S6K,S6,4EBP1,Akt) 的酸化减少表明了这一点.
P-AscH^-增强了temozolomide和mTOR抑制剂的疗效,显示出协同作用的抗癌作用.

结论:

药物酸盐通过破坏关键的DDR和mTOR信号通路,有效地准GBM.
P-AscH^-使GBM细胞对标准疗法和新药敏感,突出了其作为辅助治疗的潜力.
这些发现支持研究P-AscH^-作为质母细胞瘤和其他恶性瘤的有前途的治疗剂.

关键词:

这是一种抗癌药物.对DNA损伤的反应反应质母细胞瘤多形药理性甲酸盐是一种药理性甲酸盐.维生素C 维生素C是一种在mTOROR中使用mTOR.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...